HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goodin, S. Search for Related Content PubMed PubMed Citation Articles by Goodin, S.

SUSAN GOODIN, PHARM.D., FCCP, BCOP, is Director, Division of Pharmaceutical Sciences, the Cancer Institute of New Jersey, and Associate Professor of Medicine, the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 195 Little Albany Street, New Brunswick, NJ 08901 (goodin{at}umdnj.edu).

Purpose. The mechanisms of action and drug interactions of oral chemotherapeutic agents are reviewed. Summary. The mechanisms of action, indications, and potential for drug interactions vary for oral chemotherapy. Traditional oral chemotherapy agents cause damage to cancer cells by non-specifically interfering with cellular division. Many of the newer agents have novel targets on cancer cells preferentially, resulting in a different spectrum of toxicity. Since cancer patients are at high risk for drug interactions, usually because of age-related organ dysfunction and the need for concomitant drug therapy for comorbid conditions, understanding these agents and potential for interactions is imperative for all healthcare providers. Conclusion. Knowledge of the mechanisms and metabolic pathways for the oral chemotherapeutic agents allows the potential to predict possible drug interactions and response while minimizing the risk of adverse outcomes. Index terms: Antineoplastic agents; Drug administration routes; Drug interactions; Mechanism of action; Metabolism; Neoplasms; Pharmacokinetics; Site of action; Toxicity

 

This article has been cited by other articles:

				R. E. Eilers Jr, M. Gandhi, J. D. Patel, M. F. Mulcahy, M. Agulnik, T. Hensing, and M. E. Lacouture Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy J Natl Cancer Inst, January 6, 2010; 102(1): 47 - 53. [Abstract] [Full Text] [PDF]

				A. Chan, Y. C. Leow, and M. H. Sim Patients' perspectives and safe handling of oral anticancer drugs at an Asian cancer center Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 161 - 165. [Abstract] [PDF]

				M. Heung, B. A Mueller, and J. H Segal Optimizing Anemia Management in Hospitalized Patients with End-Stage Renal Disease Ann. Pharmacother., February 1, 2009; 43(2): 276 - 282. [Abstract] [Full Text] [PDF]

				A. L. Erickson, P. M. Szumita, and M. C. Cotugno Implementation of clinical pharmacy services in a dialysis unit Am. J. Health Syst. Pharm., November 1, 2008; 65(21): 2011 - 2013. [Full Text] [PDF]

				M. H. Mahmood, E. P. Armstrong, D. C. Malone, and G. H. Skrepnek Relationship between pharmaceutical services characteristics and exposure rates to drug-drug interactions in Veterans Affairs medical centers Am. J. Health Syst. Pharm., September 15, 2008; 65(18): 1744 - 1749. [Abstract] [Full Text] [PDF]

				S. Tomasello Anemia of Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195. [Abstract] [PDF]